Semimechanistic Pharmacokinetic-Pharmacodynamic Model with Adaptation Development for Time-Kill Experiments of Ciprofloxacin against Pseudomonasaeruginosa
暂无分享,去创建一个
Emmanuelle Comets | William Couet | W. Couet | M. Ploy | Claire Grignon | E. Comets | N. Grégoire | Manuella Marliat | Nicolas Grégoire | Sophie Raherison | Manuella Marliat | Marie-Cécile Ploy | C. Grignon | S. Raherison
[1] W. Couet,et al. Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans , 2008, Antimicrobial Agents and Chemotherapy.
[2] P. McNamara,et al. Mechanism-Based Pharmacodynamic Models of Fluoroquinolone Resistance in Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.
[3] K. Drlica,et al. DNA gyrase, topoisomerase IV, and the 4-quinolones , 1997, Microbiology and molecular biology reviews : MMBR.
[4] A. Vinks,et al. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.
[5] I. Gould,et al. Ionic binding, adaptive resistance and post-antibiotic effect of netilmicin and ciprofloxacin. , 1991, The Journal of antimicrobial chemotherapy.
[6] Mats O. Karlsson,et al. Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments , 2006, Antimicrobial Agents and Chemotherapy.
[7] M. Maciá,et al. Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.
[8] Michael Nikolaou,et al. Modelling time-kill studies to discern the pharmacodynamics of meropenem. , 2005, The Journal of antimicrobial chemotherapy.
[9] Neang S. Ly,et al. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[10] E. Bingen,et al. Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections , 2007, Antimicrobial Agents and Chemotherapy.
[11] R. MacLaren,et al. Nosocomial Infections Due to Multidrug‐Resistant Pseudomonas aeruginosa: Epidemiology and Treatment Options , 2005, Pharmacotherapy.
[12] B. Marquez. Bacterial efflux systems and efflux pumps inhibitors. , 2005, Biochimie.
[13] D. Hooper. Mechanisms of fluoroquinolone resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[14] P. Tulkens,et al. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. , 2007, The Journal of antimicrobial chemotherapy.
[15] E. Schuck,et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form* , 2005, Infection.
[16] H. Nikaido,et al. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[17] Robert Leary,et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.
[18] H. Derendorf,et al. Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.
[19] J. Ruiz. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. , 2003, The Journal of antimicrobial chemotherapy.
[20] J. Karlowsky,et al. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. , 2004, International journal of antimicrobial agents.
[21] M. Maciá,et al. Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents , 2007, Antimicrobial Agents and Chemotherapy.
[22] H. Schweizer. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. , 2003, Genetics and molecular research : GMR.
[23] G. Jacoby. Mechanisms of resistance to quinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] A. Wong-Beringer,et al. Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[25] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[26] Angela Lee,et al. MexXY-OprM Efflux Pump Is Necessary for Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides , 2003, Antimicrobial Agents and Chemotherapy.
[27] G. Manfreda,et al. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. , 2007, Veterinary microbiology.
[28] K. Rand,et al. Determination of free extracellular concentrations of piperacillin by microdialysis. , 1996, Journal of pharmaceutical sciences.
[29] H. Nikaido,et al. Involvement of an Active Efflux System in the Natural Resistance of Pseudomonas aeruginosa to Aminoglycosides , 1999, Antimicrobial Agents and Chemotherapy.
[30] P. Tulkens,et al. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. , 2003, The Journal of antimicrobial chemotherapy.
[31] K. Rodvold,et al. Pharmacokinetics and Pharmacodynamics of Fluoroquinolones , 2001, Pharmacotherapy.
[32] O. Cars,et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. , 2005, The Journal of antimicrobial chemotherapy.
[33] S. Leibler,et al. Bacterial Persistence as a Phenotypic Switch , 2004, Science.
[34] L. Rubin,et al. Stability of Antibiotics Used for Antibiotic-Lock Treatment of Infections of Implantable Venous Devices (Ports) , 1999, Antimicrobial Agents and Chemotherapy.
[35] J. Blaser,et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.
[36] A. Yamaguchi,et al. Type II Topoisomerase Mutations in Fluoroquinolone-Resistant Clinical Strains of Pseudomonas aeruginosa Isolated in 1998 and 1999: Role of Target Enzyme in Mechanism of Fluoroquinolone Resistance , 2001, Antimicrobial Agents and Chemotherapy.
[37] Y. Yamano,et al. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. , 2008, Journal of pharmaceutical sciences.